The FDA opened a new clinical trial modernization office inside the Center for Drug Evaluation and Research (CDER), aiming to speed up and improve clinical trials used to support drug approvals. The agency’s announcement ties the move to ongoing efforts to modernize trial conduct and reduce friction in generating regulatory-grade evidence. The office is positioned as an internal mechanism to address the operational challenges that commonly slow trials, including design complexity and procedural barriers. By placing the capability within CDER, the FDA is signaling it wants modernization initiatives to align directly with the agency’s review needs. The update matters for developers because it suggests near-term policy and guidance work will be coordinated around trial execution—rather than remaining solely at the level of new technology pilots. It also indicates the agency is treating trial modernization as a structural capability.